These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 35305740)

  • 21. Comparative Effectiveness of Coronavirus Disease 2019 (COVID-19) Vaccines Against the Delta Variant.
    Risk M; Shen C; Hayek SS; Holevinski L; Schiopu E; Freed G; Akin C; Zhao L
    Clin Infect Dis; 2022 Aug; 75(1):e623-e629. PubMed ID: 35137006
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness of Covid-19 Vaccines over a 9-Month Period in North Carolina.
    Lin DY; Gu Y; Wheeler B; Young H; Holloway S; Sunny SK; Moore Z; Zeng D
    N Engl J Med; 2022 Mar; 386(10):933-941. PubMed ID: 35020982
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunogenicity Following Administration of BNT162b2 and Ad26.COV2.S COVID-19 Vaccines in the Pregnant Population during the Third Trimester.
    Citu IM; Citu C; Gorun F; Sas I; Tomescu L; Neamtu R; Motoc A; Gorun OM; Burlea B; Bratosin F; Malita D
    Viruses; 2022 Feb; 14(2):. PubMed ID: 35215900
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S.
    Sadoff J; Gray G; Vandebosch A; Cárdenas V; Shukarev G; Grinsztejn B; Goepfert PA; Truyers C; Van Dromme I; Spiessens B; Vingerhoets J; Custers J; Scheper G; Robb ML; Treanor J; Ryser MF; Barouch DH; Swann E; Marovich MA; Neuzil KM; Corey L; Stoddard J; Hardt K; Ruiz-Guiñazú J; Le Gars M; Schuitemaker H; Van Hoof J; Struyf F; Douoguih M;
    N Engl J Med; 2022 Mar; 386(9):847-860. PubMed ID: 35139271
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings.
    Thompson MG; Stenehjem E; Grannis S; Ball SW; Naleway AL; Ong TC; DeSilva MB; Natarajan K; Bozio CH; Lewis N; Dascomb K; Dixon BE; Birch RJ; Irving SA; Rao S; Kharbanda E; Han J; Reynolds S; Goddard K; Grisel N; Fadel WF; Levy ME; Ferdinands J; Fireman B; Arndorfer J; Valvi NR; Rowley EA; Patel P; Zerbo O; Griggs EP; Porter RM; Demarco M; Blanton L; Steffens A; Zhuang Y; Olson N; Barron M; Shifflett P; Schrag SJ; Verani JR; Fry A; Gaglani M; Azziz-Baumgartner E; Klein NP
    N Engl J Med; 2021 Oct; 385(15):1355-1371. PubMed ID: 34496194
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness of the Ad26.COV2.S (Johnson & Johnson) Coronavirus Disease 2019 (COVID-19) Vaccine for Preventing COVID-19 Hospitalizations and Progression to High Disease Severity in the United States.
    Lewis NM; Self WH; Gaglani M; Ginde AA; Douin DJ; Keipp Talbot H; Casey JD; Mohr NM; Zepeski A; Ghamande SA; McNeal TA; Shapiro NI; Gibbs KW; Files DC; Hager DN; Shehu A; Prekker ME; Erickson HL; Gong MN; Mohamed A; Johnson NJ; Srinivasan V; Steingrub JS; Peltan ID; Brown SM; Martin ET; Monto AS; Khan A; Busse LW; Lohuis CCT; Duggal A; Wilson JG; Gordon AJ; Qadir N; Chang SY; Mallow C; Rivas C; Babcock HM; Kwon JH; Exline MC; Lauring AS; Halasa N; Chappell JD; Grijalva CG; Rice TW; Rhoads JP; Jones ID; Stubblefield WB; Baughman A; Womack KN; Lindsell CJ; Hart KW; Zhu Y; Adams K; Patel MM; Tenforde MW;
    Clin Infect Dis; 2022 Oct; 75(Suppl 2):S159-S166. PubMed ID: 35675695
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association between regular physical activity and the protective effect of vaccination against SARS-CoV-2 in a South African case-control study.
    Collie S; Saggers RT; Bandini R; Steenkamp L; Champion J; Gray G; Bekker LG; Goga A; Garrett N; Patricios J
    Br J Sports Med; 2023 Feb; 57(4):205-211. PubMed ID: 36280289
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Detection of pre-existing neutralizing antibodies against Ad26 in HIV-1-infected individuals not responding to the Ad26.COV2.S vaccine.
    Schmidt KG; Harrer EG; Schönau V; Simon D; Kleyer A; Steininger P; Korn K; Schett G; Knobloch CS; Nganou-Makamdop K; Harrer T
    Infection; 2023 Dec; 51(6):1657-1667. PubMed ID: 37067754
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vaccine effectiveness against severe COVID-19 outcomes within the French overseas territories: A cohort study of 2-doses vaccinated individuals matched to unvaccinated ones followed up until September 2021 and based on the National Health Data System.
    Semenzato L; Botton J; Baricault B; Deloumeaux J; Joachim C; Sylvestre E; Dray-Spira R; Weill A; Zureik M
    PLoS One; 2022; 17(9):e0274309. PubMed ID: 36084113
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessment of neutralizing antibody responses after natural SARS-CoV-2 infection and vaccination in congolese individuals.
    Batchi-Bouyou AL; Djontu JC; Vouvoungui JC; Mfoutou Mapanguy CC; Lobaloba Ingoba L; Mougany JS; Boumpoutou KR; Diafouka-Kietela S; Ampa R; Ntoumi F
    BMC Infect Dis; 2022 Jul; 22(1):610. PubMed ID: 35831798
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alternative strategies to increase the immunogenicity of COVID-19 vaccines in kidney transplant recipients not responding to two or three doses of an mRNA vaccine (RECOVAC): a randomised clinical trial.
    Kho MML; Messchendorp AL; Frölke SC; Imhof C; Koomen VJ; Malahe SRK; Vart P; Geers D; de Vries RD; GeurtsvanKessel CH; Baan CC; van der Molen RG; Diavatopoulos DA; Remmerswaal EBM; van Baarle D; van Binnendijk R; den Hartog G; de Vries APJ; Gansevoort RT; Bemelman FJ; Reinders MEJ; Sanders JF; Hilbrands LB;
    Lancet Infect Dis; 2023 Mar; 23(3):307-319. PubMed ID: 36354032
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differential immunogenicity of homologous versus heterologous boost in Ad26.COV2.S vaccine recipients.
    Khoo NKH; Lim JME; Gill US; de Alwis R; Tan N; Toh JZN; Abbott JE; Usai C; Ooi EE; Low JGH; Le Bert N; Kennedy PTF; Bertoletti A
    Med; 2022 Feb; 3(2):104-118.e4. PubMed ID: 35072129
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness of primary series and booster vaccination against SARS-CoV-2 infection and hospitalisation among adolescents aged 12-17 years in Singapore: a national cohort study.
    Chiew CJ; Premikha M; Chong CY; Wei WE; Ong B; Lye DC; Heng D; Lee VJ; Tan KB
    Lancet Infect Dis; 2023 Feb; 23(2):177-182. PubMed ID: 36182678
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety of a second homologous Ad26.COV2.S vaccine among healthcare workers in the phase 3b implementation Sisonke study in South Africa.
    Takalani A; Robinson M; Jonas P; Bodenstein A; Sambo V; Jacobson B; Louw V; Opie J; Peter J; Rowji P; Seocharan I; Reddy T; Yende-Zuma N; Khutho K; Sanne I; Bekker LG; Gray G; Garrett N; Goga A;
    Vaccine; 2024 Feb; 42(6):1195-1199. PubMed ID: 38278629
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
    Costa Clemens SA; Weckx L; Clemens R; Almeida Mendes AV; Ramos Souza A; Silveira MBV; da Guarda SNF; de Nobrega MM; de Moraes Pinto MI; Gonzalez IGS; Salvador N; Franco MM; de Avila Mendonça RN; Queiroz Oliveira IS; de Freitas Souza BS; Fraga M; Aley P; Bibi S; Cantrell L; Dejnirattisai W; Liu X; Mongkolsapaya J; Supasa P; Screaton GR; Lambe T; Voysey M; Pollard AJ;
    Lancet; 2022 Feb; 399(10324):521-529. PubMed ID: 35074136
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living with HIV in the Netherlands: A nationwide prospective cohort study.
    Hensley KS; Jongkees MJ; Geers D; GeurtsvanKessel CH; Mueller YM; Dalm VASH; Papageorgiou G; Steggink H; Gorska A; Bogers S; den Hollander JG; Bierman WFW; Gelinck LBS; Schippers EF; Ammerlaan HSM; van der Valk M; van Vonderen MGA; Delsing CE; Gisolf EH; Bruns AHW; Lauw FN; Berrevoets MAH; Sigaloff KCE; Soetekouw R; Branger J; de Mast Q; Lammers AJJ; Lowe SH; de Vries RD; Katsikis PD; Rijnders BJA; Brinkman K; Roukens AHE; Rokx C
    PLoS Med; 2022 Oct; 19(10):e1003979. PubMed ID: 36301821
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative vaccine effectiveness against severe COVID-19 over time in US hospital administrative data: a case-control study.
    Wright BJ; Tideman S; Diaz GA; French T; Parsons GT; Robicsek A
    Lancet Respir Med; 2022 Jun; 10(6):557-565. PubMed ID: 35227415
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Duration of vaccine effectiveness against SARS-CoV-2 infection, hospitalisation, and death in residents and staff of long-term care facilities in England (VIVALDI): a prospective cohort study.
    Shrotri M; Krutikov M; Nacer-Laidi H; Azmi B; Palmer T; Giddings R; Fuller C; Irwin-Singer A; Baynton V; Tut G; Moss P; Hayward A; Copas A; Shallcross L
    Lancet Healthy Longev; 2022 Jul; 3(7):e470-e480. PubMed ID: 35813279
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Durable antibody responses elicited by 1 dose of Ad26.COV2.S and substantial increase after boosting: 2 randomized clinical trials.
    Sadoff J; Le Gars M; Brandenburg B; Cárdenas V; Shukarev G; Vaissiere N; Heerwegh D; Truyers C; de Groot AM; Jongeneelen M; Kaszas K; Tolboom J; Scheper G; Hendriks J; Ruiz-Guiñazú J; Struyf F; Van Hoof J; Douoguih M; Schuitemaker H
    Vaccine; 2022 Jul; 40(32):4403-4411. PubMed ID: 35667914
    [TBL] [Abstract][Full Text] [Related]  

  • 40. COVID-19 mRNA vaccine effectiveness against hospitalisation and death in veterans according to frailty status during the SARS-CoV-2 delta (B.1.617.2) variant surge in the USA: a retrospective cohort study.
    Tang F; Hammel IS; Andrew MK; Ruiz JG
    Lancet Healthy Longev; 2022 Sep; 3(9):e589-e598. PubMed ID: 35935474
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.